Quick Takeaways
- ARCH Venture Fund XII, L.P. filed SCHEDULE 13D/A for Prime Medicine, Inc. Common Stock, $0.00001 par value (PRME).
- Disclosed ownership: 10%.
- Date of event: 07 Aug 2025.
ARCH Venture Fund XII, L.P. - 07 Aug 2025 SCHEDULE 13D/A Report for Prime Medicine, Inc. Common Stock, $0.00001 par value (PRME)
- Filing Manager
- ARCH Venture Fund XII, L.P.
- Reporting Manager
- Robert Nelsen
- Symbol
- PRME
- Shares outstanding
- 178,721,500 shares
- Disclosed Ownership
- 18,587,036 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13D/A
- Filing time
- 11 Aug 2025, 21:48:39 UTC
- Date of event
- 07 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ARCH Venture Fund XII, L.P. disclosed 10% ownership in Prime Medicine, Inc. Common Stock, $0.00001 par value (PRME) on 07 Aug 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 11 Aug 2025, 21:48.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (12)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | 10% | 18,486,894 | 0 | 18,486,894 | ARCH Venture Partners X, L.P. | its General Partner | 0001757011 |
| ARCH Venture Fund X Overage, L.P. | 10% | 18,486,894 | 0 | 18,486,894 | ARCH Venture Partners X Overage, L.P. | its General Partner | 0001757017 |
| ARCH Venture Fund XII, L.P. | 10% | 18,486,894 | 0 | 18,486,894 | ARCH Venture Partners XII, L.P. | its General Partner | 0001906837 |
| ARCH Venture Partners X, L.P. | 10% | 18,486,894 | 0 | 18,486,894 | ARCH Venture Partners X, LLC | its General Partner | 0001782583 |
| ARCH Venture Partners X Overage, L.P. | 10% | 18,486,894 | 0 | 18,486,894 | ARCH Venture Partners X, LLC | its General Partner | 0001768905 |
| ARCH Venture Partners XII, L.P. | 10% | 18,486,894 | 0 | 18,486,894 | ARCH Venture Partners XII, LLC | its General Partner | 0001979765 |
| ARCH Venture Partners X, LLC | 10% | 18,486,894 | 0 | 18,486,894 | /s/ Mark McDonnell | Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director | 0001769012 |
| ARCH Venture Partners XII, LLC | 10% | 18,486,894 | 0 | 18,486,894 | /s/ Mark McDonnell | Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director | 0001979548 |
| Robert Nelsen | 10% | 18,587,036 | 100,142 | 18,486,894 | /s/ Mark McDonnell | Mark McDonnell, as Attorney-in-Fact for Robert Nelsen | 0001219042 |
| Keith Crandell | 10% | 18,486,894 | 0 | 18,486,894 | /s/ Mark McDonnell | Mark McDonnell, as Attorney-in-Fact for Keith Crandell | 0001219039 |
| Kristina Burow | 10% | 18,486,894 | 0 | 18,486,894 | /s/ Mark McDonnell | Mark McDonnell, as Attorney-in-Fact for Kristina Burow | 0001569248 |
| Steven Gillis | 10% | 18,486,894 | 0 | 18,486,894 | /s/ Mark McDonnell | Mark McDonnell, as Attorney-in-Fact for Steven Gillis | 0001229592 |